GRF.MC - Grifols, S.A.
Grifols, S.A.
Avinguda de la Generalitat, 152
Parc de Negocis Can Sant Joan Sant Cugat del Valles
Barcelona 08174
Spain
34 93 571 05 00
https://www.grifols.com
Sektor(en): Healthcare
Branche: Drug Manufacturers—General
Vollzeitmitarbeiter: 24.000
Leitende Angestellte
| Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
|---|---|---|---|---|
| Mr. Thomas H. Glanzmann | Exec. Chairman | 150k | N/A | 1958 |
| Mr. Raimon Grifols Roura | Co-CEO & Exec. Vice-Chairman | 1,04M | N/A | 1964 |
| Mr. Víctor Grifols Deu | Co-CEO & Exec. Director | 1,04M | N/A | 1977 |
| Mr. Alfredo Arroyo Guerra | CFO & VP | N/A | N/A | 1958 |
| Mrs. Eva Bastida Tubau | Corp. VP and Director of Scientific & Medical Affairs | N/A | N/A | N/A |
| Ms. Nuria Pascual Lapeña | VP of Corp. Treasury, Risk Management Investor Relation & Sustainability Officer | N/A | N/A | 1964 |
| Mr. David Ian Bell | Chief Corp. Devel., Legal & Data Protection Officer | N/A | N/A | 1954 |
| Mr. Mateo Florencio Borrás Humbert | Corp. VP & Chief HR Officer | N/A | N/A | 1956 |
| Ms. Maria Teresa-Rioné Llano | Chief Communications Officer | N/A | N/A | 1965 |
| Ms. Montserrat Gaja Llamas | Chief HR Officer | N/A | N/A | 1965 |
Beschreibung
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada and internationally. The Biopharma segment provides plasma derivatives products, including Gamunex/Gamunex-C Immune Globulin Injection, Flebogamma Immune Globulin Intravenous, Xembify Immune Globulin Subcutaneous solution, HyperRAB Rabies Immune Globulin, Prolastin/Prolastin-C/Prolastin-C Liquid/Prolasplan/Prolastina/Pulmolast/Lynspad Alpha 1-Proteinase Inhibitor, Fanhdi and Alphanate, Antihemophilic Factor/von Willebrand factor Complex, Koate-DVI Antihemophilic Factor, Albutein/Albutein Flexbag/ Human Albumin Grifols/Plasbumin Albumin, and Vistaseal/Veraseal; and Tavlesse, a non-plasma derivative medicinal product. The Diagnostic segment offers transfusion medicine, which includes Procleix Panther systems/Procleix Panther with Automation Ready technology, Automated NAT blood screening systems, assays, software, WADiana/Erytra/Erytra Eflexys analyzers, BLOODchip ID/IDCore/IDHPA/IDRHD/IDCORE/BIDS, and antigens; and clinical and diagnostics products, such as Promonitor and Alpha1D. The Bio Supplies segment provides human biological materials for life sciences research and the development and manufacturing of pharmaceutical and diagnostic products. The Others segment offers healthcare solutions, which provides services and manufactures products, including parenteral solutions, robotics, and software used by hospitals, blood banks, plasma collection centers and other healthcare systems. The company's products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. Grifols, S.A. has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products, and with GIANT and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Corporate Governance
Grifols, S.A.s ISS Governance QualityScore, Stand 1. Juni 2023, lautet 4. Die grundlegenden Scores sind Audit: 2, Vorstand: 6, Shareholderrechte: 6, Kompensation: 4.
